Vaginosis, Bacterial Clinical Trial
— MAT072017Official title:
Medical Device Matuzalem Flavonoid Tea Extract Vaginal Ovule for the Correction of the Imbalance in the Vaginal Environment- Prospective, Multicentric, Two-arm, Randomized, Vehicle-controlled, Blinded, Comparative Clinical Trial
NCT number | NCT04171947 |
Other study ID # | MAT072017 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | December 4, 2017 |
Est. completion date | May 9, 2018 |
Verified date | November 2019 |
Source | Value Outcomes Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized, blinded vehicle-controlled multicenter clinical trial (MAT072017) to determine the effect of vaginal ovules containing 2 mg of the tea extract Matuzalem on the subjective symptoms (5-point scale pruritus (itching), dolor (pain), rubor (redness), fluor (discharge), and fetor (odor)), and objective symptoms (pH, Nugent score) of bacterial vaginosis. An ovule containing only the vehicle (polyethylene glycol 3000 S) was used as a control. The study was blinded from the perspective of the subject, investigator, laboratory personnel and data analyst.
Status | Completed |
Enrollment | 274 |
Est. completion date | May 9, 2018 |
Est. primary completion date | May 9, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - premenopausal participants - disturbed vaginal environment - not in need of antibiotic or antimycotic treatment - participants were citizens of the Czech Republic - age between 18 and 55 years - either a vaginal pH > 4.5 or/and vaginal discomfort - able to follow the prescribed regimen - informed consents prior to any intervention, including diagnostic procedures. Exclusion Criteria: - no vaginal bleeding of unknown aetiology - hypersensitivity - pregnancy - lactation - period during enrollment - antibiotics in the previous 30 days - treated with any products with similar indication - acute urogenital infection - diabetes mellitus - advanced oncologic disease - participant to other trial - Nugent score above 6 |
Country | Name | City | State |
---|---|---|---|
Czechia | Centrum ambulantní gynekologie a primární péce, s.r.o. | Brno | Czech Republic |
Czechia | MUDr. Milan Kucera. s.r.o. | Kladno | Czech Republic |
Czechia | MUDr. Eva Novotná - FEMCARE s.r.o. | Odolena Voda | Czech Republic |
Czechia | Gyn Por Ivf MUDr. Samer Asad s.r.o. | Prague | Czech Republic |
Czechia | GYNEDAN s.r.o. | Prague | Czech Republic |
Czechia | GYNEKOLOGIE Studentský dum s.r.o. | Prague | Czech Republic |
Czechia | Gynelav s.r.o. | Prague | Czech Republic |
Czechia | LEVRET s.r.o. | Prague | Czech Republic |
Czechia | MediStar s.r.o. | Prague | Czech Republic |
Czechia | Mediva s.r.o. | Prague | Czech Republic |
Czechia | MUDr. Michal Jelšík | Prague | Czech Republic |
Czechia | OB/GYN Associates, s.r.o. | Prague | Czech Republic |
Czechia | T.B. Gyn s.r.o. | Prague | Czech Republic |
Czechia | MUDr.Tereza Šmrhová-Kovács | Tábor | Czech Republic |
Lead Sponsor | Collaborator |
---|---|
Value Outcomes Ltd. | Matuzalem.com-cz, s.r.o. |
Czechia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite endpoint (vaginal pH, Nugent score, subjective symptoms via questionnaire) after treatment completion | Correction of the vaginal environment after 7 days of once-daily application of the ovule was defined as: a drop-in Nugent score to < 4 and/or a drop in vaginal pH to < 4.5, or a subjective improvement in at least 2 symptoms by at least 2 points on a 5-point scale in patients whose baseline pH was < 4.5 and NS < 4. Subjective symptoms: Pruritus, dolor, rubor, fluor and fetor reported by the patient on 5-point scale (0=no problem to 4=severe problem) | following 7 days of the ovule daily application | |
Secondary | Composite endpoint (vaginal pH, Nugent score, subjective symptoms via questionnaire) after 7 days since treatment completion | Correction of the vaginal environment after 7 days after treatment completion defined as: a drop-in NS to < 4 and/or a drop in vaginal pH to < 4.5, or a subjective improvement in at least 2 symptoms by at least 2 points on a 5-point scale in patients whose baseline pH was < 4.5 and NS < 4. Subjective symptoms: Pruritus, dolor, rubor, fluor and fetor reported by the patient on 5-point scale (0=no problem to 4=severe problem) | 7 days after the completion of the 7-day treatment | |
Secondary | Change in the pH alone after treatment completion | Correction of the pH measured via pH strips | following 7 days of the ovule daily application | |
Secondary | Change in the Nugent score alone after treatment completion | Nugent score determined under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Change in the subjective symptoms (questionnaire) after treatment completion | Pruritus, dolor, rubor, fluor and fetor reported by the patient on 5-point scale (0=no problem to 4=severe problem) | following 7 days of the ovule daily application | |
Secondary | Change in the pH alone after 7 days since treatment completion | Correction of the pH measured via pH strips | 7 days after the completion of the 7-day treatment | |
Secondary | Change in the Nugent score alone 7 days after treatment completion | Nugent score determined under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Change in the subjective symptoms (questionnaire) 7 days after treatment completion | Pruritus, dolor, rubor, fluor and fetor reported by the patient on 5-point scale (0=no problem to 4=severe problem) | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: squamous epithelial cells | Quantification of: squamous epithelial cells under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: squamous epithelial cells | Quantification of: squamous epithelial cells under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: clue cells | Quantification of clue cells under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: clue cells | Quantification of clue cells under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: mixed flora | Quantification of mixed flora under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: mixed flora | Quantification of mixed flora under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: yeast as pseudomycelia | Quantification of yeast as pseudomycelia under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: yeast as pseudomycelia | Quantification of yeast as pseudomycelia under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: Gram negative diplococci | Quantification of: Gram negative diplococci under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: Gram negative diplococci | Quantification of: Gram negative diplococci under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: fibrous Lactobacillus | Quantification of: fibrous Lactobacillus under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: fibrous Lactobacillus | Quantification of: fibrous Lactobacillus under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: Gardnerella | Quantification of: Gardnerella under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: Gardnerella | Quantification of: Gardnerella under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: spirochetes | Quantification of: spirochetes under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: spirochetes | Quantification of: spirochetes under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: parabasal epithelial cells | Quantification of: parabasal epithelial cells under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: parabasal epithelial cells | Quantification of: parabasal epithelial cells under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: leukocytes | Quantification of: leukocytes under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: leukocytes | Quantification of: leukocytes under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: yeast as blastospores | Quantification of: yeast as blastospores under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: yeast as blastospores | Quantification of: yeast as blastospores under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: Gram pos. cocci in chains | Quantification of: Gram pos. cocci in chains under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: Gram pos. cocci in chains | Quantification of: Gram pos. cocci in chains under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: Lactobacillus | Quantification of: Lactobacillus under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: Lactobacillus | Quantification of: Lactobacillus under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: Mobilincus | Quantification of: Mobilincus under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: Mobilincus | Quantification of: Mobilincus under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: Leptotrichia | Quantification of: Leptotrichia under 1000x magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: Leptotrichia | Quantification of: Leptotrichia under 1000x magnification | 7 days after the completion of the 7-day treatment | |
Secondary | Exploratory analysis of the microbial environment after treatment completion: Trichomonas vaginalis | Quantification of: Trichomonas vaginalis under 1000 magnification | following 7 days of the ovule daily application | |
Secondary | Exploratory analysis of the microbial environment after 7 days after treatment completion: Trichomonas vaginalis | Quantification of: Trichomonas vaginalis under 1000 magnification | 7 days after the completion of the 7-day treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT02558179 -
Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method
|
N/A | |
Completed |
NCT02272231 -
Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women
|
||
Completed |
NCT02314429 -
Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis
|
Phase 1 | |
Completed |
NCT02139839 -
Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14
|
Phase 0 | |
Recruiting |
NCT01448291 -
Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers
|
Phase 4 | |
Recruiting |
NCT03500107 -
Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial
|
N/A | |
Completed |
NCT00153517 -
Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy
|
Phase 2 | |
Completed |
NCT04989543 -
Study of the Composition and Bacterial Diversity of the Vaginal Microbiota in Healthy Versus Pathological Conditions (Bacterial Vaginosis) Using a Targeted Metagenomic Approach (RNA 16s)
|
N/A | |
Completed |
NCT02641717 -
Validity of Patient-Collected Wet Mounts
|
N/A | |
Terminated |
NCT03943823 -
Postmenopausal Pessary Users: Estrogen Versus Trimosan
|
Phase 4 | |
Completed |
NCT03134924 -
Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention "WASH-2"
|
N/A | |
Completed |
NCT01293643 -
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
|
Phase 3 | |
Terminated |
NCT01153958 -
Colposeptine for the Treatment of Bacterial Vaginosis
|
Phase 4 | |
Completed |
NCT00484653 -
Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman
|
N/A | |
Completed |
NCT05649735 -
EFFICACY AND SAFETY OF OVA AND LAVAGE MEDICAL DEVICES IN THE TREATMENT OF NON-SPECIFIC VULVOVAGINITIS
|
N/A | |
Completed |
NCT02860845 -
Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections
|
Phase 4 | |
Not yet recruiting |
NCT00491270 -
Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery
|
Phase 3 | |
Completed |
NCT01055106 -
Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis
|
Phase 2 | |
Terminated |
NCT01322971 -
Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population
|
N/A | |
Completed |
NCT02392026 -
Safety and Tolerability of Metronidazole Gel 1.3%
|
Phase 4 |